Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands Published as part of the ACS Pharmacology & Translational Science virtual special issue "GPCR Signaling".

被引:3
|
作者
Olson, Keith M. [1 ,2 ,3 ]
Campbell, Andra [1 ,2 ,3 ]
Alt, Andrew [1 ,2 ,3 ]
Traynor, John R. [1 ,2 ,4 ]
机构
[1] Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Edward F Domino Res Ctr, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Life Sci Inst, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA
关键词
GPCRs; agonist efficacy; drug discovery; conformational biosensor; nanobody; biased agonist; PROTEIN-COUPLED RECEPTOR; MU-OPIOID RECEPTOR; STABILIZED ACTIVE STATE; STRUCTURAL INSIGHTS; CRYSTAL-STRUCTURE; ALLOSTERIC MODULATORS; AGONIST-BINDING; RAPID DISCOVERY; AT1; ANGIOTENSIN; DYNAMIC PROCESS;
D O I
10.1021/acsptsci.1c00256
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
G protein-coupled receptors (GPCRs) are highly druggable targets that adopt numerous conformations. A ligand's ability to stabilize specific conformation(s) of its cognate receptor determines its efficacy or ability to produce a biological response. Identifying ligands that produce different receptor conformations and potentially discrete pharmacological effects (e.g., biased agonists, partial agonists, antagonists, allosteric modulators) is a major goal in drug discovery and necessary to develop drugs with better effectiveness and fewer side effects. Fortunately, direct measurements of ligand efficacy, via receptor conformational changes are possible with the recent development of conforma-tional biosensors. In this review, we discuss classical efficacy models, including the two-state model, the ternary-complex model, and multistate models. We describe how nanobody-, transducer-, and receptor-based conformational biosensors detect and/or stabilize specific GPCR conformations to identify ligands with different levels of efficacy. In particular, conformational biosensors provide the potential to identify and/or characterize therapeutically desirable but often difficult to measure conformations of receptors faster and better than current methods. For drug discovery/development, several recent proof-of-principle studies have optimized conformational biosensors for high-throughput screening (HTS) platforms. However, their widespread use is limited by the fact that few sensors are reliably capable of detecting low-frequency conformations and technically demanding assay conditions. Nonetheless, conformational biosensors do help identify desirable ligands such as allosteric modulators, biased ligands, or partial agonists in a single assay, representing a distinct advantage over classical methods.
引用
收藏
页码:694 / 709
页数:16
相关论文
empty
未找到相关数据